Driehaus Capital Management LLC Purchases New Stake in CeriBell (NASDAQ:CBLL)

Driehaus Capital Management LLC acquired a new stake in CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 280,005 shares of the company's stock, valued at approximately $7,247,000. Driehaus Capital Management LLC owned 0.78% of CeriBell as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Rhumbline Advisers purchased a new position in CeriBell in the fourth quarter worth $320,000. Bank of New York Mellon Corp purchased a new position in CeriBell in the fourth quarter worth $628,000. Charles Schwab Investment Management Inc. purchased a new position in CeriBell in the fourth quarter worth $2,500,000. PNC Financial Services Group Inc. purchased a new position in CeriBell in the fourth quarter worth $47,000. Finally, Vanguard Group Inc. purchased a new position in shares of CeriBell in the fourth quarter valued at $18,015,000.

Insider Buying and Selling at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 5,700 shares of the company's stock in a transaction that occurred on Thursday, April 17th. The stock was sold at an average price of $15.02, for a total value of $85,614.00. Following the transaction, the chief executive officer now directly owns 746,451 shares of the company's stock, valued at $11,211,694.02. This represents a 0.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 24,700 shares of company stock valued at $372,434 in the last three months.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective on the stock. Canaccord Genuity Group reiterated a "buy" rating and set a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell currently has a consensus rating of "Buy" and an average target price of $32.50.

CeriBell Stock Up 4.9%

NASDAQ:CBLL traded up $0.81 during trading hours on Thursday, hitting $17.27. The stock had a trading volume of 165,368 shares, compared to its average volume of 274,295. CeriBell has a 1-year low of $10.01 and a 1-year high of $32.75. The firm has a 50 day simple moving average of $17.70.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The business had revenue of $20.49 million during the quarter, compared to analyst estimates of $19.30 million. On average, equities analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.